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ABSTRACT
Ongoing tissue repair and formation and deposition of collagen-rich extracellular matrix in tissues and organs finally 
lead to fibrotic lesions and destruction of normal tissue/organ architecture and function. In the lung, scarring is observed 
in asthma, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis to various degrees. At the cellular 
level immune cells, fibroblasts and epithelial cells are all involved in fibrotic processes. Mechanistically, fibroblast to 
myofibroblast transformation and epithelial to mesenchymal transition are major drivers of fibrosis. Amongst others, 
both processes are controlled by transforming growth factor beta-1 (TGFβ-1), a growth factor upregulated in idiopathic 
pulmonary fibrosis lungs. Phenotypic assays with primary human cells and complex disease-relevant readouts become 
increasingly important in modern drug discovery processes. We describe high-content screening based phenotypic as-
says with primary normal human lung fibroblasts and primary human airway epithelial cells. For both cell types, TGFβ-1 
stimulation is used to induce fibrotic phenotypes in vitro, with alpha smooth muscle actin and collagen-I as readouts for 
FMT and E-cadherin as a readout for EMT. For each assay, a detailed image analysis protocols is described. Treatment 
of both cell types with TGFβ-1 and a transforming growth factor beta receptor inhibitor verifies the suitability of the as-
says for pharmacological interventions. In addition, the assays are compatible for siRNA and Cas9-ribonucleoprotein 
transfections, and thus are useful for genetic target identification/validation by modulating gene expression.
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INTRODUCTION
Fibrosis is a process of continuous tissue repair characterized by the 
formation and deposition of fibrillary, collagen-rich extracellular matrix 
(ECM) leading to a progressive remodeling in most tissues and organs. 
Formation of fibrotic scar tissue is essential to restore and maintain 
tissue and organ integrity during wound healing after injury. Howev-
er, when the scarring mechanisms exacerbate after repetitive injury, 
chronic fibrogenesis results in a shift from supportive fibrotic tissue 
to scar tissue. This coincides with an increased number and activity of 
extracellular matrix producing cells, which finally leads to destruction 
of normal tissue/organ architecture and function [1,2].
In the lung, tissue scarring/fibrosis occurs to a different extend in 
diseases like asthma, chronic obstructive pulmonary disease (COPD) 
and idiopathic pulmonary disease (IPF). After tissue damage, activa-
tion of the immune system induces release of several cytokines and 
growth factors including transforming growth factor beta-1 (TGFβ-1) 
that signals the tissue to repair [3,4]. Mechanistically, epithelial to 
mesenchymal transition (EMT) is one of the major drivers of fibrosis, 
and approximately 30% of ECM-producing (myo-)fibroblasts derive 
from epithelial cells through EMT [5]. During EMT, tightly organized 
epithelial cells lose expression of the tight junction marker E-cadherin 
[6,7] and transform to mesenchymal cells with expression of the mesen-
chymal cell markers N-cadherin, vimentin and fibronectin. Furthermore, 
the cells gain migratory potential, enabling to migrate throughout the 
tissue [7-9]. Another important mechanism during fibrosis is fibroblast 
to myofibroblast transformation (FMT), when EMT-derived, resident 
and invading fibroblastoid cells are activated (e.g., by TGFβ-1) and start 
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to differentiate towards myofibroblasts. Myofibroblasts are a heteroge-
neous population derived from different progenitors, characterized by 
formation of alpha smooth muscle actin (aSMA) containing stress fibers 
and the expression and secretion of fibrillar collagen, fibronectin and 
additional ECM components. Increased production and accumulation of 
ECM result in a permanently damaged fibrotic tissue with an aberrant 
architecture unable to function properly [1,7].
Phenotypic disease-relevant cellular assays are becoming more 
and more relevant in modern drug discovery. Phenotypic assays try to 
modulate disease-relevant phenotypes without an assumption about the 
specific target or mechanism of action [10]. For a successful phenotypic 
screen Vincent et al. [11] recently published the “rule of 3”: (1) The 
assay system needs to have a clear link to the disease either by the use 
of human primary or iPSC-derived cells; (2) The assay readout should 
be as close as possible to the disease pathobiology; and (3) as the use 
of an exogenous stimulus to induce a disease phenotype often results 
in identification of stimulus- instead of disease-modifying mechanisms, 
the authors recommend to use assays which are independent on ex-
ogenous stimuli [11]. For the phenotypic assays using either primary 
normal human lung fibroblasts (NHLF) to monitor FMT (collagen-I 
and aSMA readout) or primary human small airway epithelial cells 
(hSAEC) to model EMT (E-cadherin readout), the rules (1) and (2) are 
accomplished. The FMT and EMT assays described in the literature 
[12-17] rely on TGFβ-1 as a stimulus to induce FMT or EMT. However, 
as TGFβ-1 levels are higher in IPF lungs compared to lungs of healthy 
controls [18,19], and as TGFβ-1 is at least partially responsible for the 
exaggerated matrix deposition within the fibrotic lung [20-22], induction 
of both FMT and EMT with TGFβ-1 does not violate the third rule.
Phenotypic screening assays with primary human cells can be used 
for both pharmacological and genetic drug target identification and 
validation. Modulating gene expression in cells has been primarily 
achieved using RNAi technologies. RNAi mediated gene repression 
relies on either transfection of synthetic siRNAs, plasmid-encoded 
shRNAs or transduction of shRNA encoding viral particles. However, 
RNAi reagents are frequently prone to off-target effects. Therefore, hits 
from RNAi screens should be validated intensively, also by the use of 
orthogonal technologies, e.g., Crispr-Cas9 system in order to exclude 
potential off-target activities responsible for the observed phenotype 
[23]. So far, only a small number of studies successfully applied the 
Crispr-Cas9 technology to primary cells. Frequently, Cas9 and the 
sgRNA are virally delivered to the cells [13,24,25]. However, virally 
mediated Cas9-sgRNA delivery is time consuming with respect to virus 
generation and restricts its application to a lower throughput, unless a 
screen can be performed in a pooled format [26]. Recently, it has been 
shown that Cas9 and sgRNAs can be transfected in cells as Cas9-RNPs 
(ribonucleoproteins) [27,28]. Recombinant Cas9 and synthetic sgRNAs 
or cr:trRNAs are commercially available and thus enable the time 
effective screening of sg/cr:trRNA libraries by Cas9-RNP transfection.
We recently described a primary human lung fibroblast assay to 
study effects of lysyl oxidase (like) family member knock downs on 
TGFβ-1-dependent FMT with aSMA as a readout [29]. In the present 
study, we described a further optimized version of this assay, not only 
measuring aSMA as marker of myofibroblast formation, but also in-
cluding ECM components, collagen-I and fibronectin as readouts. In 
addition, we delineated an EMT assay with E-cadherin as a readout. In 
combination with pharmacological and genetic methods, these assays 
are useful tools for compound characterization, target identification and 
validation in a higher throughput format. We showed that both assays 
exhibit a dose dependent responsiveness to TGFβ-1 and are pharma-
cologically modulated by TGFβ-1 receptor inhibitors (Alk5 inhibitor, 
Alk5i). In addition, they are compatible with siRNA and Cas9-RNP 
transfections to study gene function.
MATERIALS AND METHODS
Materials
Normal human lung fibroblasts (NHLF), human small airway epi-
thelial cells (hSAEC) and cell culture media (FBM and SABM media 
plus corresponding SingleQuots) were from Lonza. The supplier guar-
antees informed consent from the donors to use the cells for research 
purposes. Phosphate buffered saline (PBS), Triton-X-100, formaldehyde, 
carbonate solution, vitamin C, bovine serum albumin (BSA), methanol, 
mouse monoclonal anti-collagen-I and anti-alpha smooth muscle actin 
antibodies and tumor growth factor beta-1 were from Sigma. Sigma 
also provided the Alk5i SB-525334. HEPES, HBSS, OptiMEM, mouse 
anti-E-cadherin antibody, secondary goat anti-mouse-IgG1-AF568 and 
anti-mouse-IgG2a-AF647 antibodies, RNAiMAX siRNA transfection 
reagent, TaqMan gene expression kits, High-Capacity cDNA Reverse 
Transcription Kit, AmpliTaq Gold 360 Master Mix, HCS Cell Mask Green 
and Hoechst 33342 nuclear dye were purchased from ThermoFisher. 
The anti-fibronectin antibody ab6328 was delivered by Abcam. Inte-
grated DNA Technologies (IDT) provided recombinant Cas9 protein 
and the Cas9 electroporation enhancer, GE Healthcare Ficoll 70 and 
100. From Dharmacon, synthetic Edit-R-crispr-, -tracrRNAs (Edit-R 
Human TGFBR1 crRNA: CM-003929-03-0002.; Edit-R Human ACTA2 
crRNA: CR-003450-02; Edit-R DNMT3B Control Kit: U-007010-
05; Edit-R CRISPR-Cas9 Synthetic tracrRNA: U-002005-05) and 
synthetic ON-Traget Plus SMART Pool siRNAs (ON-TARGETplus 
Non-targeting Pool: D-001810-10-05; ON-TARGETplus TGFBR1: 
L-003929-00-0005; ON-TARGETplus ACTA2: L-003450-00-0005) 
were purchased. Edit-R lentiviral Basticidin-Cas9-Nuclease expressing 
particles were obtained from Dharmacon. Poly-D-lysine coated 384 
well microtiter plates suitable for image acquisition and analysis were 
delivered by PerkinElmer. For Cas9-RNP electroporation, the Nucleo-
fector System and 96-well shuttle device together with the Nucleofector 
Primary Solution P3 from Lonza was used. RNeasy Plus 96 Kit was 
from Qiagen. Direct PCR Lysis Reagent was from Peqlab, proteinase 
K from Macherey Nagel. Poly-D-lysine coated 384 well CellCarrier 
microtiter plates were purchased from Perkin Elmer.
Fibroblast to myofibroblast transformation assay
At day 0, for compound testing (e.g., Alk5i) 1000 NHLF cells were 
plated in full medium (FMB plus Single Quots) in poly-D-lysine coated 
384 well CellCarrier microtiter plates. 24 h later (day 1), cells were washed 
3 times with HBSS/10 mM Hepes/0.0375% carbonate buffer and starved 
in medium without SingleQuots for 24 h. At day 2 post seeding, medium 
was replaced with FBM medium containing TGFβ-1, 200 µM vitamin 
C, 37.5 mg/ml Ficoll 70 and 25 mg/ml Ficoll 400. Where indicated the 
Alk5i diluted in medium with 0.1% DMSO was included. In siRNA 
and Cas9-RNP transfection experiments, 0.1% FCS was included in 
the starvation buffer throughout the assay. At the end of the assay (day 
5), cells were fixed for 30 min on ice with methanol, 3 times washed 
with PBS and permeabilized with PBS/1% Triton-X-100 for 20 min at 
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ambient temperature. Followed by 3 wash steps with PBS, non-specific 
antibody binding was reduced by a blocking step with 3%BSA in PBS 
for 30 min at ambient temperature. Antibodies targeting collagen-I 
and aSMA, each diluted 1:1000 were added to the cells for 1 h at 37°C 
after an additional wash step with PBS. The anti-fibronectin antibody 
was used in a final concentration of 0.05 µg/ml. Primary antibodies 
were removed by 3 wash steps with PBS and the secondary antibodies 
labeled with AF568 for the anti-collagen-I- and anti-fibronectin-IgG1 
and AF647 for the anti-aSMA-IgG2a diluted 1:1000 were incubated 
for 30 min at 37°C together with the nuclear dye Hoechst. Antibodies 
were removed by 3 washes with PBS and cell cytoplasm was stained 
by addition of 1:50000 diluted HCS CellMaskGreen dye for 30 min at 
ambient temperature. After an additional PBS washing step, plates were 
sealed and images were acquired with an IN Cell Analyzer 2200. Nu-
clear, cytoplasm, aSMA and collagen-I or aSMA and fibronectin images 
were acquired in the DAPI, FITC, Cy7 and Cy5 channels, respectively.
Images were transferred to Perkin Elmer´s Columbus Image Storage 
and Analysis system. Image analysis was performed using a custom 
made image analysis protocol (Table S1), with total number of cells, 
number of fiber-like αSMA structures/cell and total collagen/fibronec-
tin area/total number of cells as parameters used to quantify effects of 
compounds (e.g., Alk5i), siRNAs and Cas9-RNPs.
Epithelial to mesenchymal transition assay
For the EMT assay, 4000 hSAECs/well were seeded in a poly-D-lysine 
coated 384 CellCarrier microtiter plate at day 0. Day 1 post seeding me-
dium was exchanged after 3 washes with HBSS/10 mM Hepes/0.0375% 
carbonate buffer. 24 h later (day 2), medium was replaced with medium 
containing TGFβ-1. Where the Alk5i was indicated was included in 
medium with 0.1% DMSO. After 72 h, cells were fixed with 2% form-
aldehyde containing 1 µM Hoechst 33342 to stain nuclei for 30 min 
at ambient temperature. Following 3 washes with PBS, non-specific 
antibody binding was blocked by incubation with 2%BSA in PBS for 
30 min at ambient temperature. The blocking solution was removed by 
3 wash steps with PBS, and the cells were incubated with the primary 
mouse-anti-E-cadherin antibody (final concentration 0.4 µg/ml) for 1 h 
at 37°C. Three washes with PBS were followed by an incubation with 
the secondary AF568-labed goat anti-mouse-IgG1 (1:1000 diluted) for 
1 h at 37°C. Following 3 PBS wash steps, cells were permeabilized with 
0.1% Triton-X-100 for 20 min at ambient temperature, washed again 
and incubated for 30 min at ambient temperature with HCS CellMask 
Green (1:50000 diluted). Images were acquired with a PerkinElmer Op-
era Phenix High Content Screening System, after a final wash step and 
plate sealing. Nuclear, cytoplasm and Ecadherin images were acquired 
in the Hoechst, AF488 and AF568 channels, respectively.
Images were transferred to Perkin Elmer’s Columbus Image Storage 
and Analysis system. Image analysis was performed using a custom 
made image analysis protocol (Table S2), with total number of cells, 
(total E-cadherin intensity × total E-cadherin area) / (total cell number) 
as parameters used to quantify effects of compounds (e.g., Alk5i), 
siRNAs and Cas9-RNPs.
siRNA transfections
Transfection of siRNAs in NHLF cells for the FMT assay was 
performed 6 h after cell seeding. A transfection mix for one well in a 
384 well mictrotiter plate with 2000 cells in 70 µl FBM medium with 
SingleQuots consisted of 0.2 µl RNAiMAX, 56 nM siRNA in 20 µl 
FBM medium, resulting in a final siRNA concentration of 16 nM/well. 
The 4000 hSAECs per well for the EMT assay were transfected with 
a similar transfection cocktail, in which FBM medium was replaced 
by OptiMEM. All transfection mixtures were incubated for 20 min at 
ambient temperature to form transfection complexes before addition 
to the cells. 24 h after transfection, the transfection complexes were 
removed and the assays were continued as described above.
Gene expression analysis
For determination of siRNA mediated gene knock down, cells were 
lysed and RNA was prepared using the RNeasy Plus 96 Kit accord-
ing to the manufacture’s protocol. 2 µg of total RNA was reverse 
transcribed with the High-Capacity cDNA Reverse Transcription Kit 
as described in the supplier’s protocol. qPCR with 2µl of cDNA and 
gene-specific TaqMan Assays (TGFBR1: Hs00610320_m1; ACTA2: 
Hs00909449_m1, RNA-polymerase II amplification primers: GCAAG-
CGGATTCCATTTGG and TCTCAGGCCCGTAGTCATCCT, probe: 
AAGCACCGGACTCTTGCCTCACTTCATC) was performed as 
suggested in the manual. The relative gene-specific knock down was 
calculated as percentage knock down compared to control siRNA treated 
cells after normalization to RNA polymerase II expression.
Cas9-RNP transfections
For Cas9-RNP transfections, each 200 µM Edit-R-crRNA and Ed-
it-R-trRNA were hybridized by incubation for 5 min at 95°C and cooling 
to ambient temperature. The RNPs were formed by incubating 20.74 
µM recombinant Cas9 protein, with 24 µM cr:trRNA duplexes in a 
total volume of 5 µl. Complex formation was achieved by incubation 
for 20 min at ambient temperature. For controls without Cas9 protein, 
cr:trRNA duplexes were incubated with 20.74 µM BSA instead of Cas9. 
Next, the RNP complexes were mixed with either 100000 NHLF cells 
or hSAECs in 20 µl Nucleofector Solution P3 plus 1 µl electroporation 
enhancer, and electroporated with Nucleofector program 96-EH-100 or 
96-DC-100 for NHLF and hSAEC cells, respectively. Electroporated 
NHLF cells and hSAECs were resuspended in 375 µl of their respective 
medium with SingleQuots and 5000 (NHLF) or 10000 (hSAEC) cells 
were seeded in one well of a 384 microtiter plate. Again, 24 h after 
transfection the transfection complexes were removed and the assays 
were continued as described above.
Generation and transfection of Cas9-expressing NHLF 
cells
NHLF cells constitutively expressing Cas9 were generated by trans-
duction of 100000 NHLF cells with Edit-R lentiviral EF1a-Bastici-
din-Cas9-Nuclease expressing particles at a MOI of 1. 24 h after trans-
duction, medium was exchanged and selection for genomic integration 
of the viral genome was started by addition of 8 µg/ml Blasticidin S. 
After 4 passages, cell stocks were prepared and used for FMT assays 
essentially as described above, with the duplexed cr:trRNAs directly 
transfected without prior RNP formation.
Gene editing analysis
Gene editing efficiency was determined by PCR amplification of 
the edited genomic loci, followed by Sanger sequencing and the use 
of the Inference of CRISPR editing (ICE) tool [30]. After removal of 
cell culture medium, 15 µl of PCR lysis reagent containing 0.2 mg/
ml Proteinase K was added to each well of a 384 microtiter plate and 
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incubated for 2 h at 55°C under constant agitation. The lysis reaction 
was stopped by heating the reaction to 85°C for 45 min. 5 µl crude cell 
lysate was amplified with 10 µM of each forward and reverse PCR 
primers (TGFBR1_F: AAATTCAGTGACTTTTGGTG, TGFBR1_R: 
GAGTTTCAGCAATGATATGT; ACTA2_F: TTATTTGGAGGCAAT-
TCAGG, ACTA2_R: TGTGGTGTTCTGTATCAGAGA; DMNT3B_F: 
TGAGAAGGAGCCACTTGCTT, DMNT3B_R: GACCAAGAACG-
GGAAAGTCA) using AmpliTaq Gold 360 MasterMix for 35 cycles 
with an annealing temperature of 50°C. The amplicons were 425, 406 
and 544 bp in length. Purified PCR products were Sanger sequenced 
using the PCR forward primers.
Data analysis
All data obtained were further processed and analyzed using Graph-
Pad Prism7®, version 7.03. Statistical significance was calculated using 
a Student’s t-test.
RESULTS
TGFβ-1-mediated fibroblast-to-myofibroblast transition 
assay
We used normal primary human lung fibroblasts to establish a TG-
Fβ-1-dependent FMT assay with aSMA, collagen-I and fibronectin as 
high content screening based readouts (Fig. 1A).
A specific image analysis script was developed as described in the 
Materials and Methods section (see also Table S1). The aSMA signal was 
not evenly dispersed throughout the whole cytoplasm, but seen in fiber 
like structures, reflecting the incorporation of newly translated aSMA 
into the F-actin cytoskeleton. Rising concentrations of TGFβ-1 induced a 
dose-dependent increase in aSMA and collagen-I with an EC
50
 of 1.5 and 
2 ng/ml (Fig. 1B). An effect of TGFβ-1 on cell numbers was not observed 
(Fig. S1A). TGFβ-1-mediated collagen-I expression is only detectable, 
if the cells were treated with the molecular crowding agent Ficoll in the 
presence of vitamin C (Fig. S1B). A TGFβ-1 concentration of 5 ng/ml 
reproducibly induced aSMA and collagen-I expression submaximally 
(approximately EC
90
), and was chosen for all further experiments. Cal-
culation of z´-values as a statistical parameter for assay quality resulted 
in z´-values of 0.7 ± 0.047, 0.69 ± 0.035 and 0.2 ± 0.134 for aSMA, 
collagen-I and fibronectin, respectively (for n = 10 different plates with 
n = 38 non-TGFβ-1- and n = 24 5 ng/ml TGFβ-1-treated wells). To 
validate the TGFβ-1-mediated effects on FMT, cells were preincubated 
with a TGF receptor kinase inhibitor (Alk5i) before stimulation with 
TGFβ-1. As expected, the Alk5i dose-dependently inhibited aSMA, 
collagen-I and fibronectin expression (Fig. 1C and Fig. S1C) with an 
IC
50
 value of 0.16 µM, 0.19 µM and 0.6 µM for aSMA, collagen-I and 
fibronectin, respectively. Alk5i induced inhibition of TGFβ-1-mediated 
aSMA expression was tested in 3 additional donors and the potency was 
comparable between the different donors. However, donor 1 showed 
a less prominent induction of aSMA expression after stimulation with 
TGFβ-1 (Fig. S1D). Due to the lower z´-value for fibronectin and the 
co-staining of either aSMA and fibronectin or aSMA and collagen-I, 
collagen-I was selected as the extracellular matrix component to be 
analyzed in all further experiments.
TGFβ-1-mediated epithelial-to-mesenchymal transition 
assay
Primary human small airway epithelial cells were used for the TG-
Fβ-1-dependent EMT assay with E-cadherin (Ecad) as a high content 
screening based readout (Fig. 2A). The corresponding image analysis 
script is described in Material and Methods section and Table S2. In 
the EMT assay, TGFβ-1 stimulation led to a signal decrease. Increasing 
doses of TGFβ-1 gradually reduced Ecad expression, reaching a mini-
mum of 10 ng/ml. Therefore, 10 ng/ml TGFβ-1 was used as the standard 
concentration for all further experiments. Preincubation with 10 µM 
Alk5i before addition of TGFβ-1 restored Ecad expression to levels even 
higher than in non-TGFβ1-treated cells (Fig. 2B). Analysis of additional 
donors revealed similar effects of TGFβ-1 and the Alk5i plus TGFβ-1 
(Fig. S2). The calculated Alk5i-IC
50
 for inhibition of Ecad expression 
determined from a dose-response curve was 0.12 µM (Fig. 2C) which 
was comparable to its effects on TGFβ-1-stimualted FMT. The assay 
quality parameter z´-value was 0.68 for this specific experiment, and 
generally was in a similar range (0.6 ± 0.08, for n = 9 different plates 
with n = 32 non-TGFβ-1- and n = 52 10 ng/ml TGFβ-1-treated wells).
Genetic modulation of gene expression in phenotypic 
FMT and EMT assays with siRNAs
To test whether the described human primary cell-based FMT and 
EMT phenotypic assays could be used to modify gene expression 
levels by siRNA transfection, we performed proof-of-concept assays, 
in which we either reduced TGFBR1 (FMT and EMT) or ACTA2 
(FMT) expression. siRNA-mediated knock down of TGFBR1, one 
of the signaling receptor kinases of TGFβ-1, should result in a sim-
ilar reduction of the aSMA/collagen-I expression for FMT and Ecad 
expression for EMT as observed by an Alk5i treatment of the cells. In 
the FMT assay, knock down of TGFBR1 led to a complete absence of 
aSMA and collagen-I expression. In addition to the TGFβ-1 receptor 
knock down, we also reduced ACTA2 expression with corresponding 
siRNAs. Again, the knock down completely abolished aSMA expression 
with only marginal effects on collagen-I expression. For both genes 
the knock down efficiency was more than 90% (Fig. 3A). In the EMT 
assay in the absence of TGFβ-1, the knock down of TGFBR1 already 
induced Ecad expression, comparable to an Alk5i. TGFβ-1 treatment 
reduced Ecad expression only in control siRNA (siCT) transfected and 
non-transfected cells, but not in TGFBR1 siRNA transfected cells, again 
showing the specificity of the siRNA and the TGFβ-1-depencency of 
the assay (Fig. 3B). The knock down efficiency of TGFBR1 in the EMT 
was determined to be higher than 90%.
Genetic modulation of gene expression in phenotypic 
FMT and EMT assays using Crispr-Cas9
Next, we established an orthogonal technology to siRNA based modu-
lation of gene expression. Therefore, we investigated if Cas9-RNP-trans-
fections are compatible with our FMT and EMT assays. We used 
synthetic crRNAs hybridized to a synthetic trRNA and incorporated in 
a ribonucleoprotein complex together with recombinant Cas9 protein. 
To assess specificity cells were transfected with hybridized cr:trRNAs 
incubated with BSA instead of Cas9 protein. In the FMT assay, TG-
FBR1-Cas9-RNPs strongly reduce the aSMA and collagen-I signal. 
Similar to the siACTA2 transfection, the transfection of a Cas9-RNP 
targeting ACTA2 resulted in a strong reduction of aSMA expression with 
only minor effects on collagen-I expression. Control transfections with 
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BSA instead of Cas9 were without any effects on both aSMA and coll-I 
expression (Fig. 4A and 4B). Determination of Cas9-RNP-mediated 
gene editing by an ICE analysis revealed an editing efficiency of around 
70% for both ACTA2- and TGFBR1-Cas9-RNPs (Fig. 4B). Although 
the editing efficiency is less compared to the siRNA mediated knock 
down efficiency of both ACTA2 and TGFBR1, the effects on aSMA 
and collagen-I expression are similar. In addition to Cas9-RNP trans-
fections, we generated a pool of recombinant NHLF cells by lentiviral 
transduction, in which Cas9 was stably expressed. After transfection 
of cr:trRNA duplexes targeting ACTA2 and TGFBR1, the effects on 
TGFβ-1-mediated FMT was analyzed. Again, ACTA2 and TGFBR1 
cr:trRNAs reduced aSMA expression. Collagen-I expression was only 
affected in TGFBR1-targeted cell. However, the level of aSMA and 
collagen reduction was not as pronounced as in siRNA or Cas9-RNP 
transfected cells. Compared to Cas9-RNP transfections, the editing 
efficiencies after cr:trRNA transfection in Cas9-expressing cells was 
lower (Fig. 4C).
Figure 1. Phenotypic FMT assay. A. Schematic representation of the FMT assay with time points of treatment and readouts. At the end of the assay 
cells were prepared for high content imaging for alpha smooth muscle actin (αSMA) and collagen I (Coll-I) expression. B. Images of NHLF cells treated 
with increasing doses of TGFβ-1, stained for nuclei, αSMA and Coll-I. Images were acquired with an IN Cell 2200 high content imager (left). Number of 
αSMA expressing fibers/cell and Coll-I area/cell was quantified with the described custom protocols using the Columbus software and plotted against 
cumulating doses of TGFβ-1 (right). The TGFβ-1 EC50 was 1.5 and 2 ng/ml for αSMA and Coll-I, respectively. C. Immunofluorescence images of NHLF 
cells stimulated with 5 ng/ml TGFβ-1 and increasing concentrations of the Alk5i SB-525334 (left). The Alk5i dose-dependently inhibited αSMA and Coll-I 
expression (right) with an IC50 of 0.16 µM and 0.19 µM for αSMA and Coll-I, respectively.
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Figure 2. Phenotypic EMT assay. A. Schematic representation of the EMT assay with time points of treatment and readouts. At the end of the assay 
cells were prepared for high content imaging on E-cadherin expression. B. Images of hSAEC treated with increasing doses of TGFβ-1 and stained for 
nuclei and Ecad. Images were acquired with an Opera Phenix High Content Screening System (right). Ecad/ total cell numbers was quantified with a 
custom protocol using Columbus software and plotted against cumulating doses of TGFβ-1. From this data 10 ng/ml TGFβ-1 for all further experiments was 
chosen. C. Immunofluorescence images of hSAECs stimulated with 10 ng/ml TGFβ-1 and progressive concentrations of the Alk5i SB-525334 (right). The 
Alk5i dose-dependently inhibited the TGFβ-1-mediated reduction of Ecad expression an IC50 of 0.12 µM (left). *P < 0.05 versus non-TGFβ-1 treated cells. 
Transfections in hSAECs were done with Cas9-RNPs targeting 
either TGFBR1 or DMNT3B, a positive control for gene editing sold 
by Dharmacon. In mock transfected cells, 10 ng/ml TGFβ-1 lead to a 
complete loss of Ecad expression. Transfection with Cas9-RNPs tar-
geting DMNT3B or the respective BSA control did not interfere with 
TGFβ-1-driven EMT (as seen by complete absence of Ecad staining). 
However, Cas9-RNPs targeting TGFBR1 abolished EMT with an even 
higher expression of Ecad compared to mock and BSA controls. This is 
similar to the effects of an Alk5i and siRNAs targeting TGFBR1. For 
the TGFBR1 and DMNT3B Cas9-RNPs, the editing efficiencies were 
greater than 90% and 60%, respectively (Fig. 5).
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Figure 3. siRNA mediated knock down of ACTA2 and/or TGFBR1 in primary human cell phenotypic assays. A. NHLF cells were transfected with 
siRNAs targeting ACTA2 (siACTA2) and TGFBR1 (siTGFBR1). ACTA2 and TGFBR1 KD reduced αSMA expression in the presence of TGFβ-1 stimulation. 
TGFBR1 KD, but not ACTA2 decreased Coll-I expression. Both siRNAs efficiently reduced their mRNA expression by more than 90% compared to control 
siRNA (siCT) transfected cells. B. Non-treated and TGFβ-1-treated hSAECs were incubated with transfection reagent only (TFR) or transfection reagent 
plus siTGFBR1 or siCT and stained for Ecad expression. TGFBR1-KD completely abolished TGFβ-1-mediated reduction of Ecad expression. TGFBR1 
mRNA expression was reduced by > 90% by siTGFBR1 transfection. Note, TGFβ-1 increases TGFBR1 expression about 3-fold. *P < 0.05 versus siCT.
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Figure 4. Crispr-Cas9 mediated knock out of ACTA2 and/or TGFBR1 in the FMT assay. A. NHLF cells were transfected with Cas9-cr:trRNA-RNPs 
targeting ACTA2 (crACTA2) and TGFBR1 (crTGFBR1). ACTA2 and TGFBR1 knock out reducedαSMA expression, whereas Coll-I expression was dimin-
ished only by Cas9-RNPs targeting TGFBR1, but not ACTA2. B. Quantitative analysis of images shown in (A) (right and middle) and editing efficiency 
calculated in ICE (left). Editing efficiencies for ACTA2 and TGFBR1-RNP are both > 80%. *P < 0.05 versus BSA-crRNA transfected cells. C. ACTA2 
and TGFBR1 cr:trRNA transfection in NHLF cells constitutively expressing Cas9. In contrast to TGFβ-1-treated NHLF cells, mock transfected NHLF 
cells without TGFβ-1 are devoid of αSMA and Coll-I expression. ACTA2- and TGFBR1-cr:trRNA transfection reduced αSMA expression less than the 
corresponding Cas9-RNP transfections. Again Coll-I expression was not affected by an ACTA2 knock out. TGFBR1-cr:trRNA transfection diminished 
Coll-I expression (right and middle). Editing efficiencies are at least 50% in Cas9 expressing cells, which is lower as in Cas9-RNP transfected cells. *P 
< 0.05 versus mock transfected cells treated with TGFβ-1.
DISCUSSION
Amongst a plethora of different cell types and mechanisms contribut-
ing to fibrogenesis, fibroblasts and FMT and epithelial cells transforming 
to mesenchymal cells, a mechanism named EMT are of major impor-
tance in fibrotic diseases [2,31,32]. Phenotypic screening assays with 
disease relevant readouts become increasingly popular in the last years 
as it is thought that they are more predictive for the clinical therapeutic 
response [10,33,34]. Indeed, in a recent phenotypic screen aiming to 
identify antifibrotic compounds, a compound identified in the cellular 
screen showed activity in a preclinical animal model of fibrosis [35]. In 
the present study, we described two assays using human primary cells 
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(NHLF and hSAEC) in combination with phenotypic readouts (aSMA, 
collagen-I, fibronectin and E-cadherin) to study the fibrotic mechanisms 
FMT and EMT in vitro. We stimulated both cell types with the profi-
brotic growth factor TGFβ-1 and investigated the performance of both 
assays as screening tools for identification of antifibrotic compounds 
and as screening assays for genetic target identification and validation 
assays. For the latter, we used either siRNA mediated knock down or 
Crispr-Cas9 mediated knock out approaches.
Figure 5. Crispr-Cas9 mediated knock out of TGFBR1 and DMNT3B in the EMT assay. hSAECs were either mock transfected (Cas9 replaced 
by BSA) or with Cas9-cr:trRNA-RNPs targeting TGFBR1 (crTGFBR1) and DMNT3B (crDMNT3B). In mock transfected cells TGFβ-1 repressed Ecad 
expression. TGFBR1 knock out abolished Ecad repression completely, whereas a DMNT3B knock out did not alter Ecad expression. Editing efficien-
cy for TGFBR1- and DMNT3B-RNPs were at least 60%. *P < 0.05 versus BSA-crRNA transfected cells, #: mock transfected, TGFβ-1 treated versus 
mock-transfected non-TGFβ-1-treated cells.
Our first goal was to establish and pharmacologically validate a FMT 
and an EMT assay with primary human pulmonary cells compatible 
with high content screening readouts and sophisticated image analysis 
tools to obtain robust screening assays. Several recently described 
FMT assays [13,35,36] simply measure aSMA fluorescence intensity. 
As for myofibroblast contraction the incorporation of aSMA in F-actin 
fibers is required [37], we developed a protocol enabling the quanti-
fication of aSMA incorporated in the F-actin stress fiber cytoskeleton 
as fiber-like structures per cells, which resulted in a very robust assay 
window with excellent assay statistics (i.e., z´-value). A similar image 
analysis script was published recently [38]. These authors described 
a FMT assay which measured the expression of procollagen, but not 
mature collagen. We included in our FMT assay, apart from aSMA and 
fibronectin mature collagen. Usually, fibrogenic cells in monolayer cell 
culture do not produce significant amounts of mature collagen albeit 
full procollagen expression [39]. However, addition of macromolecules 
like dextran sulfate of Ficoll enhanced mature collagen production 
via an artificial crowding effect [39-41]. In our FMT assay, we used 
a mixture of Ficoll 70 and 400 as a macromolecular crowding agent. 
For both fibronectin and collagen-I quantification, we developed an 
image analysis protocol detecting the total fibronectin/collagen-I area 
normalized to the total cell number. At least for collagen-I expression, 
we obtained very good assay statistics. The final image analysis protocol 
for the EMT assay quantified the total Ecad fluorescence × total area of 
Ecad staining per total cell number. This value delivered a highly robust 
assay statistic. With the optimized assays and analysis protocols, we 
clearly showed that both assays can be modulated by different TGFβ-1 
concentrations and that a TGFβ-1 receptor kinase inhibitor (the Alk5i 
SB-525334) dose-dependently reduced aSMA and collagen-I (and 
fibronectin) expression in the FMT assay. In the EMT assay, the Alk5i 
dose-dependently inhibited the TGFβ-1-mediated reduction in Ecad 
expression. In addition, we observed that the Alk5i is able to restore 
the amount of Ecad to levels higher than in non-TGFβ-1 treated cells. 
The reason for this could be that TGFβ-1 in the fetal calf serum which 
is included in the hSAEC medium already dampened Ecad expression 
in non-stimulated cells. When this medium-derived TGFβ-1 activity is 
inhibited together with the exogeneously added TGFβ-1 activity, Ecad 
levels might rise even higher compared to non-TGFβ-1 treated cells. 
This is in line with experiments in which the TGFBR1 was ablated by 
either siRNA or Cas9-RNPs resulting in Ecad levels higher than in those 
observed in non-TGFβ-1 treated cells. The submicromolar potency of 
the Alk5i SB-525334 in this study is comparable to published poten-
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cies in other fibrotic assays [35,36,42]. With the robustness, also with 
respect to the relative donor-independent reproducibility, it should be 
feasible to run at least medium throughput phenotypic fibrosis screens 
to identify either new chemical matter for further optimization or new 
targets in case annotated libraries.
For genetic target identification or validation, we could show that 
the assays can be used to transfect both siRNAs and Cas9-RNPs. We 
recently used siRNA transfections in the FMT assay with aSMA as a 
readout to study the role lysyl oxidase (like) family members in pulmo-
nary fibrosis [29]. In this study, we extended the previously described 
FMT assay by the collagen-I and fibronectin readouts and described an 
advanced image analysis protocol for the 3 different readouts using the 
Columbus software instead of the IN Cell Developer Software which 
we used before [29]. Implementation of automated siRNA transfection 
would enable siRNA screens up to a genome-wide format in primary 
human fibroblasts of both healthy and diseased donors, comparable to 
the screen described in Oh et al., using IMR-90 fibroblast cells. The 
EMT assay is again a high throughput amenable phenotypic assay in 
primary human airway epithelial cells, and when combined with siR-
NA transfections should enable target identification/validation screens 
comparable to successfully described siRNA screens in non-airway 
epithelial cell lines [43,44].
Having shown that the primary cell based FMT and EMT assays 
can be used to genetically interfere with gene expression by RNAi 
technologies, we were also interested in if we could adapt the assays 
for use of the Crispr-Cas9 gene editing technology. Recently, adenoviral 
mediated introduction of the both Cas9 and sgRNAs in primary human 
fibroblasts and epithelial cells in the context of FMT and EMT was 
published [13]. However, we wanted to transfect the primary cells with 
commercially available reagents. Therefore, electroporation conditions 
were established for both NHLF cells and hSAEC to transfect recom-
binant Cas9 protein complexed in a RNP with a cr:trRNA duplex. We 
obtained editing efficiencies by ICE analysis of ≥ 60% for 3 different 
genes in the 2 different cell types. This is several fold higher compared 
to published indel frequencies, which were determined by T7 mismatch 
assays after Cas9-RNP transfection or adenoviral Cas9-sgRNA delivery 
in primary cells [13,45]. Surprisingly, both the phenotypic effects and 
the editing efficiencies of NHLF cells stably expressing Cas9 after 
cr:trRNA transfection were smaller compared to cells transfected with 
Cas9-RNPs. Similar, Seki and Rutz [46] showed superior effects of 
Cas9-RNPs compared to lentivirally delivered sgRNA-Cas9 all-in-one 
vector constructs. Different gene editing efficiencies observed between 
RNP transfected and lentivirally delivered sgRNAs might be related 
to the higher Cas9 protein amount on a per cell basis. However, Cas9 
protein levels were not measured in our experiments. Apart from the 
higher editing efficiencies, Cas9-RNPs are associated with reduced 
off-target effects due to the shorter half-life of the Cas9-RNP in compar-
ison to e.g., sgRNA-Cas9 lentiviral transductions [47]. To complement 
the genetic toolbox with phenotypic readouts, the CrisprA and CrisprI 
technology for transcriptional activation and inhibition [26,48] could 
be established for primary human cell assays.
In summary, in this study we showed that primary human pulmonary 
cells from different donors can be used to successfully establish FMT 
and EMT phenotypic assays for identification and characterization of 
pro- and anti-fibrotic compounds. Both assays were amenable to genetic 
modulation with RNAi and Crispr-Cas9 technologies. Combined with 
a FACS-able readout, both assays might also be modified to run pooled 
genetic screens [26]. A FMT assay with FACS-able aSMA readout in 
primary human fibroblasts was already published [49].
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